Cheerleaders for diabetes heavyweight Novo Nordisk (NOV: N) have been reassured by positive top-line data from a Phase II trial of its semaglutide plus cagrilintide candidate, Cagrisema.
Underscoring the significance of the data, shares in the company rose fully 4% in Copenhagen on Monday.
The firm has taken the lead in the treatment of obesity with its Wegovy (semaglutide), the first GLP-1 agonist approved for weight loss, and a candidate that has proven itself to be highly effective in clinical trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze